Text Size

Personalized Prevention of Colorectal Cancer Trial

This study is currently recruiting participants.
Verified April 2012 by Vanderbilt University
Sponsor:
Information provided by (Responsible Party):
Qi Dai, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT01105169
First received: April 14, 2010
Last updated: April 27, 2012
Last verified: April 2012
History of Changes
  Purpose

Colorectal cancer is the fourth most common incident cancer and the second most common cause of cancer death in the United States, with approximately 150,000 new cases and 57,000 deaths per year. High calcium intake and magnesium may protect against colorectal cancer and adenoma, however, results have been inconsistent. We found that genetic makeup, associated with magnesium absorption and re-absorption, significantly interacted with the calcium and magnesium ratio in relation to the both adenomatous and hyperplastic polyps. Participants who carried at least one 1482Ile allele (G->A)of TRPM7 and who consumed diets with a high calcium/magnesium ratio were at a higher risk of adenoma and hyperplastic polyps than were participants who did not carry the polymorphism. We hypothesize that the reduction in the dietary Ca/Mg ratio may change the markers directly related to tumorigenesis. The primary aims of this study are to conduct a randomized placebo-controlled intervention trial to test whether reducing the Ca/mg intake ratio through magnesium supplementation has effects on the related biomarkers. We will also examine whether the effect of modulating Ca/Mg intake ratio may be more pronounced among those who carry the 1482Ile allele compared those who don't carry the 1482Ile allele. Results from our study will help to identify people at a high risk of colorectal adenoma and to develop personalized strategies to prevent occurrence of colorectal adenoma, and thus, colorectal cancer through dietary change or nutritional fortification.


Condition Intervention
Colorectal Cancer
 Dietary Supplement: Magnesium glycinate
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Investigational Nutrigenetic Studies for Cancer Prevention

Resource links provided by NLM:

Drug Information available for: Magnesium
U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • biomarkers directly related to tumorigenesis [ Time Frame: Assays of biomarkers will be performed at year 1, 2, 3, 4 and 5 of the study. ] [ Designated as safety issue: No ]

Estimated Enrollment: 240
Study Start Date: August 2010
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: GG genotype and magnesium treatment
Participants who have the GG genotype will be assigned to magnesium treatment.
 Dietary Supplement: Magnesium glycinate
Oral administration of magnesium supplements daily for 12 weeks
Placebo Comparator: GG genotype and placebo
Participants who have the GG genotype will be assigned to placebo group
 Dietary Supplement: Placebo
Oral administration of identical-appearing placebo daily for 12 weeks
Active Comparator: GA/AA genotype and magnesium treatment
Participants who have the GA/AA genotype will be assigned to magnesium treatment
 Dietary Supplement: Magnesium glycinate
Oral administration of magnesium supplements daily for 12 weeks
Placebo Comparator: GA/AA genotype and Placebo
Participants who have the GA/AA genotype will be assigned to placebo group
 Dietary Supplement: Placebo
Oral administration of identical-appearing placebo daily for 12 weeks

  Eligibility

Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adenoma cases from the TCPS study (IRB # 090235) or from Vanderbilt University Hospital
  • Consent to be contacted for future studies in TCPS (IRB # 090235)
  • Participants with a calcium intake ≥ 700 mg/day measuring with 24 hour dietary recalls
  • Participants with a calcium intake < 2000 mg/day measuring with 24 hour dietary recalls
  • Participants with a calcium/magnesium intake ratio > 2.6
  • Participants with known genotype for Thr1482Ile polymorphism in TRPM7
  • Non African-American
  • Will live in Nashville or surrounding area in the next 6 months

Exclusion Criteria:

  • Intolerance to magnesium glycinate or microcrystalline cellulose (placebo)
  • Chronic renal diseases and hepatic cirrhosis
  • Chronic ischemic heart disease with unstable angina, chronic heart failure at class III or IV and acute myocardial infarction in the last 6 months
  • Chronic diarrhea
  • Current breastfeeding
  • Current or planned pregnancy
  • Type I diabetes mellitus
  • Pituitary dwarfism
  • Use of digoxin and licorice
  • Current use of blood anticoagulant drugs such as Dicumarol(Warfarin), Clopidogrel (Plavix), Prasugrel HCl (Efficent), Ticlopidine (Ticlid), Lovenox (Enoxaparin), Fragmin (Dalteparin), Innohep (Tinzaparin), Eptifibatide (Integrilin), Tyrofiban (Aggrastat), and Abciximab (Reopro)
  • Current use of lithium carbonate therapy (Eskalith, Lithobid, Lithonate, Lithotabs, Apo-Lithium carbonate, Apo-Lithium carbonate SR, Carbolth, Duralith, PMS-Lithium carbonate, PMS-Lithium citrate)
  • Individuals with a history of colon resection or colectomy due to any reason
  • Individuals with any history of cancer other than non-melanoma skin cancer
  • Individual with history of any organ transplantation
  • Individuals with Inflammatory bowel disease
  • Individuals if creatinine clearance is < 50
  • Currently institutionalized
  • Homeless individual (address, telephone etc.)
  • Unable to provide informed consent
  • Any condition that in the opinion of the investigator raises concerns about protocol compliance
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01105169

Contacts
Contact: Xinqing Deng, MD, MPH 615-343-6951 Xinqing.Deng@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt Medical Center Recruiting
Nashville, Tennessee, United States, 37203
Contact: Xinqing Deng, MD     615-343-6951     xinqing.deng@vanderbilt.edu    
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Qi Dai, MD, PhD Vanderbilt University
Principal Investigator: Chang Yu, PhD Vanderbilt University
Principal Investigator: Martha J Shrubsole, Ph.D. Vanderbilt University
  More Information

No publications provided

Responsible Party: Qi Dai, Associate Professor, Vanderbilt University
ClinicalTrials.gov Identifier: NCT01105169     History of Changes
Other Study ID Numbers: 100106
Study First Received: April 14, 2010
Last Updated: April 27, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
Personalized prevention
Colorectal cancer
Investigational Nutrigenetic Studies
Magnesium
Gene polymorphism

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
 Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on May 19, 2013